Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Presentation delivered by Raksha Joshi, Chief Medical Officer, Medical Director, Monmouth Family Health Center at the marcus evans National healthcare CMO Summit 2019 held in texas
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion of the CADTH Symposium
● Recommendations for HTA improvements in Canada
● Audience Q&A
View the video: https://youtu.be/AJCOemf2r6Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public Affairs
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on disparities in provincial reimbursement for cancer medications, and what patients can do about it
● Explanation of the different ways that cancer treatments are managed and funded across Canada, and outline the impact this has on patients depending on where they live in the country
View the video: https://youtu.be/NN3AcGYMXac
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
During this webinar, attendees will learn about:
- The role that drug access navigators play in Canada, and why they are needed.
- The challenges drug access navigators face on a daily basis.
- How drug access navigators can help you.
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Presentation delivered by Raksha Joshi, Chief Medical Officer, Medical Director, Monmouth Family Health Center at the marcus evans National healthcare CMO Summit 2019 held in texas
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion of the CADTH Symposium
● Recommendations for HTA improvements in Canada
● Audience Q&A
View the video: https://youtu.be/AJCOemf2r6Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public Affairs
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on disparities in provincial reimbursement for cancer medications, and what patients can do about it
● Explanation of the different ways that cancer treatments are managed and funded across Canada, and outline the impact this has on patients depending on where they live in the country
View the video: https://youtu.be/NN3AcGYMXac
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
During this webinar, attendees will learn about:
- The role that drug access navigators play in Canada, and why they are needed.
- The challenges drug access navigators face on a daily basis.
- How drug access navigators can help you.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Takeaways from a roundtable held on June 1st about patient-centred pharmacare in Canada
● Reports from patient groups and other subject matter experts
● A cohesive vision and set of values for national pharmacare in Canada
View the video: https://youtu.be/HMy_gsTDkfI
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A review of the responses from each of the federal political parties received by CCSN to its federal election questionnaire.
● Insights on each party’s health care platform with an emphasis on how those positions might affect cancer care.
● Commentary from two veteran cancer patient advocates: Colleen Savage of the Cancer Advocacy Coalition of Canada and Kathy Barnard of the Save Your Skin Foundation, who will discuss their interpretations of the party positions and what they might mean for patients and the cancer care after the election.
Contact the presenters:
● gjeffcott@3sixtypublicaffairs.com
● colleensavage@rogers.com
● kathysaveyourskin@icloud.com
View the video: https://youtu.be/1BVyYfpnZEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Gerry Jeffcott, of 360 Public Affairs, gave a presentation for the CCSN on the drug approval process in Canada on March 27, 2014. He outlines the divide between public and private networks, cost management, as well as the review and approval process for pharmaceuticals in Canada.
The Canadian Cancer Survivor Network (CCSN) conducted a survey in April 2013 the discover the impact that being involved in volunteer advocacy and/or the development of public policy has on cancer patients, survivors, caregivers and family members. 51 people completed the survey. Findings were that patient advocacy generally has a positive impact on the self-image of those doing it, that many volunteer advocates felt better, prouder, more useful, more hopeful, more effective and more powerful. Still others felt less angry, less anxious, and less sad. But some survey respondents did feel sadder, angrier, less hopeful and less content. CCSN recommends that organizations ensure that cancer patients involved in advocacy activities receive skills to help them and support to deal with the often slow-moving and sometimes frustrating healthcare, cancer care and government systems in Canada.
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
Insights will be provided by a panel of representatives from other chronic disease patient advocacy organizations who will discuss how they interact with health systems, successfully advocate, and help each other through the ongoing journey of dealing with a chronic illness.
Contact the presenters:
●
●
●
View the video: https://youtu.be/QIQKAUmuEJA
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share these slides with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on how new treatments are reviewed and approved for sale in this country, with a particular emphasis on Health Canada’s regulatory modernization initiative
● Explanation of patient involvement in Health Canada reviews as well as the special access program.
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Join Alexandra Chambers & oncologist Dr. Craig Earle with CADTH's pan-Canadian Oncology Drug Review (pCODR) as they discuss the opportunities for clinicians to participate in the process and be part of the system, and how clinician input can help to inform cancer drug funding recommendations to enhance patient outcomes for Canadians.
3Sixty Public Affairs' Bill Dempster moderated this interactive webinar that included opportunities for participants to participate in polling and ask questions.
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Webinar Information:
The cancer survivor community knows the statistics about cancer all too well: that nearly half of all Canadians will develop cancer over the course of their lives, and that a quarter of them are forecasted to die from the disease. There are dozens of less prevalent cancer types that face significant and different challenges in terms of organization, research and support. The prognosis for many rare cancers is improving as new treatments are developed, however, in Canada, getting access to new therapies and clinical trials is one of many challenges faced by small communities often struggling with the disease and dealing with life’s myriad other challenges.
This webinar will explore what individual caregivers can do, how groups can work together to pool resources and share best practices and information, and provide concrete recommendations for the broader cancer community in Canada. You will learn more about how patients are working with each other, and with the clinical and research community and health systems, to improve the lives of Canadians affected by rare cancers!
Presenters:
• David Josephy, President of GIST Sarcoma Life Raft Group Canada
• Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada
• Durhane Wong-Rieger, President & CEO of the Canadian Organization for Rare Disorders (CORD)
• Bill Dempster, 3Sixty Public Affairs
View the video: https://youtu.be/L3mqpu-iFU0
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Don't miss our upcoming webinars! Subscribe today.
In this webinar:
1) Attendees will be provided with an overview of the drug approval and reimbursement processes.
2) People will be taken through a review of the updated CADTH patient group/clinician input processes.
3) Everyone will have a better understanding of how the processes are connected and flow into one another.
View the YouTube video here: https://youtu.be/-Bv9DZvSITk
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Takeaways from a roundtable held on June 1st about patient-centred pharmacare in Canada
● Reports from patient groups and other subject matter experts
● A cohesive vision and set of values for national pharmacare in Canada
View the video: https://youtu.be/HMy_gsTDkfI
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A review of the responses from each of the federal political parties received by CCSN to its federal election questionnaire.
● Insights on each party’s health care platform with an emphasis on how those positions might affect cancer care.
● Commentary from two veteran cancer patient advocates: Colleen Savage of the Cancer Advocacy Coalition of Canada and Kathy Barnard of the Save Your Skin Foundation, who will discuss their interpretations of the party positions and what they might mean for patients and the cancer care after the election.
Contact the presenters:
● gjeffcott@3sixtypublicaffairs.com
● colleensavage@rogers.com
● kathysaveyourskin@icloud.com
View the video: https://youtu.be/1BVyYfpnZEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Gerry Jeffcott, of 360 Public Affairs, gave a presentation for the CCSN on the drug approval process in Canada on March 27, 2014. He outlines the divide between public and private networks, cost management, as well as the review and approval process for pharmaceuticals in Canada.
The Canadian Cancer Survivor Network (CCSN) conducted a survey in April 2013 the discover the impact that being involved in volunteer advocacy and/or the development of public policy has on cancer patients, survivors, caregivers and family members. 51 people completed the survey. Findings were that patient advocacy generally has a positive impact on the self-image of those doing it, that many volunteer advocates felt better, prouder, more useful, more hopeful, more effective and more powerful. Still others felt less angry, less anxious, and less sad. But some survey respondents did feel sadder, angrier, less hopeful and less content. CCSN recommends that organizations ensure that cancer patients involved in advocacy activities receive skills to help them and support to deal with the often slow-moving and sometimes frustrating healthcare, cancer care and government systems in Canada.
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
Insights will be provided by a panel of representatives from other chronic disease patient advocacy organizations who will discuss how they interact with health systems, successfully advocate, and help each other through the ongoing journey of dealing with a chronic illness.
Contact the presenters:
●
●
●
View the video: https://youtu.be/QIQKAUmuEJA
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share these slides with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on how new treatments are reviewed and approved for sale in this country, with a particular emphasis on Health Canada’s regulatory modernization initiative
● Explanation of patient involvement in Health Canada reviews as well as the special access program.
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Join Alexandra Chambers & oncologist Dr. Craig Earle with CADTH's pan-Canadian Oncology Drug Review (pCODR) as they discuss the opportunities for clinicians to participate in the process and be part of the system, and how clinician input can help to inform cancer drug funding recommendations to enhance patient outcomes for Canadians.
3Sixty Public Affairs' Bill Dempster moderated this interactive webinar that included opportunities for participants to participate in polling and ask questions.
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Webinar Information:
The cancer survivor community knows the statistics about cancer all too well: that nearly half of all Canadians will develop cancer over the course of their lives, and that a quarter of them are forecasted to die from the disease. There are dozens of less prevalent cancer types that face significant and different challenges in terms of organization, research and support. The prognosis for many rare cancers is improving as new treatments are developed, however, in Canada, getting access to new therapies and clinical trials is one of many challenges faced by small communities often struggling with the disease and dealing with life’s myriad other challenges.
This webinar will explore what individual caregivers can do, how groups can work together to pool resources and share best practices and information, and provide concrete recommendations for the broader cancer community in Canada. You will learn more about how patients are working with each other, and with the clinical and research community and health systems, to improve the lives of Canadians affected by rare cancers!
Presenters:
• David Josephy, President of GIST Sarcoma Life Raft Group Canada
• Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada
• Durhane Wong-Rieger, President & CEO of the Canadian Organization for Rare Disorders (CORD)
• Bill Dempster, 3Sixty Public Affairs
View the video: https://youtu.be/L3mqpu-iFU0
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Don't miss our upcoming webinars! Subscribe today.
In this webinar:
1) Attendees will be provided with an overview of the drug approval and reimbursement processes.
2) People will be taken through a review of the updated CADTH patient group/clinician input processes.
3) Everyone will have a better understanding of how the processes are connected and flow into one another.
View the YouTube video here: https://youtu.be/-Bv9DZvSITk
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
On July 7, 2014, the Green Park Collaborative (GPC) of the Center for Medical Technology Policy (CMTP) and the Institute for Clinical and Economic Review (ICER) co-hosted a web conference to explore the evidence needed to demonstrate the effectiveness and value of new drugs to treat chronic hepatitis C (HCV) infection. Representatives from various stakeholder groups, including payers, patients, pharmaceutical industry, health technology assessment organizations, and regulatory bodies, presented and discussed this issue with a particular focus on:
1. The evidence generated for regulatory approval;
2. The evidence preferences of post-approval decision makers; and
3. Strategies to efficiently generate the additional evidence.
Each of the invited speakers gave a brief presentation followed by a question and answer session at the end of the presentations. Audience members had an opportunity to submit questions through a chat feature. The conference was moderated by Dr. Sean Tunis, Founder
and CEO of CMTP. More than 200 participants, including a variety of subject matter experts and stakeholder representatives, attended the web conference.
Video and webinar summary available here: http://www.cmtpnet.org/featured-projects/green-park-collaborative/gpc-usa-meetings/webinars/hepatitis-c-drugs-evidence-to-demonstrate-effectiveness-value
Federally Qualified Health Centers must provide all required primary, preventive and enabling health services, in addition to additional health services, as appropriate and necessary. This can be managed either directly through health center employees and volunteers, or through formal written contracts and formal written referral arrangements.
It is important for health centers to understand that contracts and formal written referral arrangements are not just a piece of paper and not only come with requirements, but also responsibilities on the part of both the health center and the contracted/referral provider(s).
This webinar will address the following:
• HRSA required clinical language for Column II contracts and Column III formal written referral arrangements
• The responsibilities of the health center and the contracted/referral provider
• A high-level review of the clinical chapters associated with Column II and Column III contracts
• Case studies demonstrating gaps in care creating areas of significant risk
• Best Practices to ensure appropriate continuity and quality of care
Are you a new FQHC? Or new to an FQHC? Wondering what FTCA coverage is all about? How do you prepare to be ready to apply for coverage?
Get answers to these questions and more in this introductory webinar that will benefit everyone
Accessing Diabetes Education Through TelehealthTAOklahoma
M. Dianne Brown, MS, RDN, LD, CDE
OU Physicians Diabetes Life Clinic at the Harold Hamm Diabetes Center
Cynthia Scheideman-Miller, MHSA
Heartland Telehealth Resource Center
Oklahoma Telemedicine Conference 2014: Telehealth Transition
October 16, 2014
Keeping with its promises, Association of the British Pharmaceutical Industry has launched a clinical-trial disclosure toolkit to help its member businesses observe with transparency needs for information from or about clinical trials.
Keeping with its promises, Association of the British Pharmaceutical Industry has launched a clinical-trial disclosure toolkit to help its member businesses observe with transparency needs for information from or about clinical trials.
About this Webinar: This presentation will discuss the pathway to pharmaceutical treatments in Canada that involve health technology assessment reviews and decision making. Observations on the current challenges and the importance of patient input to inform decision making will also be discussed. Finally, the key elements that can be critical to successful outcomes will be presented.
How to Avoid Being a Target in the Mental Health Outpatient WorldPYA, P.C.
PYA Consulting Manager Lori Baker recently presented "How to Avoid Being a Target in the Mental Health Outpatient World" at the Florida Council for Community Mental Health 2017 Behavioral Health Conference. The presentation covered: -General discussion related to Intensive Outpatient Programs (IOPs)
-Documentation requirements and admission criteria for accurate orders to IOPs
-How to appropriately document the need for ongoing IOP services
-Defining the appropriate language to support that a group environment benefits the patient
-Additional best practices for IOP services
-How to evaluate when payers may consider services a “social” service/environment as opposed to a therapeutic environment
-Telehealth in the IOP world and the compliance implications associated with this service
Similar to PDPT Webcast - Part 3 - The Law and CFHC Requirements (20)
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
PDPT Webcast - Part 3 - The Law and CFHC Requirements
1. PDPT Law in California and
CFHC PDPT Guidelines
Requirements for Participation in
CFHC’s PDPT Distribution Program
advocate facilitate evaluate educate research
2. CFHC’s PDPT Trainings
• This is Part 3 of a 3-part series on PDPT
– Part 1: Background information about PDPT
– Part 2: Using PDPT for Partner Management
– Part 3: PDPT Law in California and
CFHC PDPT Guidelines
• For more information on PDPT:
http://www.cdph.ca.gov/pubsforms/Guidelines/Documents/CA-STD-PDPT-Guideline
advocate facilitate evaluate educate research
3. Background
advocate facilitate evaluate educate research
4. CDC Supports PDPT!
“EPT should be available to clinicians as an
option for partner management”
- Expedited Partner Therapy in the Management of Sexually Transmitted
Diseases, http://www.cdc.gov/std/treatment/EPTFinalReport2006.pdf
advocate facilitate evaluate educate research
5. CDC Recommendations:
Does not replace other partner management
strategies
Used in situations in which the partner is not
likely to receive treatment in a clinical setting.
Along with medication, EPT should be
accompanied by:
Educational materials
Information that advises recipients about how to
seek personal health care in addition to EPT
advocate facilitate evaluate educate research
6. Is PDPT for CT and GC Legal in
California?
YES!
2001 - State law in California allows clinicians to
provide treatment to partners of patients with
chlamydia
January 1, 2007 - law also allows PDPT for
gonorrhea
advocate facilitate evaluate educate research
7. Legal Status of EPT in the U.S.
*As of 02/2012
advocate facilitate evaluate educate research
9. California Guidelines
Patient-Delivered Partner Therapy (PDPT) for
Chlamydia trachomatis and Neisseria gonorrhoeae:
Interim* Guidance for Medical Providers in California
Developed by: California Department of Public Health Sexually Transmitted
Diseases (STD) Control Branch in collaboration with California STD Controllers
Association, the California STD/HIV Prevention Training Center, and the
California Chlamydia Action Coalition.
*Published in 2011, based on 2007 PDPT Guidance and have been revised to include updated
gonorrhea treatment recommendations for dual therapy and precautions relations to pharyngeal
gonorrhea infections.
http://www.cdph.ca.gov/pubsforms/Guidelines/Documents/CA-STD-PDPT-Guidelines-1
www.std.ca.gov
advocate facilitate evaluate educate research
11. CFHC PDPT Distribution Program:
Background
Neither Medi-Cal nor Family PACT reimburse
PDPT medication
Therefore, CFHC provides FREE PDPT to Title X
Delegate Agencies to increase access to
partner treatment.
advocate facilitate evaluate educate research
12. CFHC PDPT Distribution Program
Requirements
1. Medication must be:
Distributed free-of-charge to clients
Prescribed solely to chlamydia- or gonorrhea-positive
clients for treatment of their partners (i.e., use is
restricted to patient-delivered partner therapy or
take-home medication for partners)
OR to uninsured clients eligible for Title X services,
but not eligible for the Family PACT program.
advocate facilitate evaluate educate research
13. CFHC PDPT Distribution Program
Requirements
2. Each dispensing clinic must maintain a
medication log.
The log must include:
Date of visit
Patient identifier (i.e. medical record
number or name)
Patient date of birth and gender.
advocate facilitate evaluate educate research
14. CFHC PDPT Distribution Program
Requirements
Sample PDPT Log
advocate facilitate evaluate educate research
15. CFHC PDPT Distribution Program
Requirements
A copy of each site’s log will be requested at
the end of the 2nd and 4th quarters.
These logs and a sample of patient charts may
be reviewed during your agency’s next Title X
site evaluation.
advocate facilitate evaluate educate research
16. CFHC PDPT Distribution Program
Requirements
Samples of the chlamydia PDPT patient education
handouts in English, Spanish, Chinese, and
Vietnamese are available for free on the CFHC
website, as well as gonorrhea PDPT patient
education handouts in English and Spanish.
http://www.cfhc.org/Resources/SamplesFile/sexuall
y-transmitted-disease.html
advocate facilitate evaluate educate research
17. Questions?
For CFHC PDPT Program information, please
contact:
Aileen Barandas MSN, NP
STD Programs Director
barandasa@cfhc.org
510.486.0412 ext 2334
advocate facilitate evaluate educate research
18. Medical and scientific consultation for this
webcast was provided by the California
Department of Public Health, STD Control
Branch
For more information, please visit
www.std.ca.gov
advocate facilitate evaluate educate research
Editor's Notes
Hello, and welcome to the California Family Health Council’s webcasts about Patient Delivered Partner Therapy, or PDPT. I’m Linda Creegan, family nurse practitioner with the California STD/HIV Prevention Training Center.
This webcast is Part 3 of a 3-part series about partner delivered partner therapy. In this segment, I’ll be discussing California law as it relates to PDPT, and the California Family Health Council’s Azithromycin distribution program for PDPT. Please listen to Parts 1 and 2 for more information about the important background information about chlamydia and gonorrhea infections, and about the specifics of using PDPT in your clinic settings.
First, a bit of background regarding
In 2006, the CDC released a document called Expedited Partner Therapy in Sexually Transmitted Diseases, which includes guidance about using patient delivered partner therapy. CDC clearly supports the use of PDPT, by stating that expedited partner therapy should be available to clinicians as an option for partner management.
As discussed in the previous webcasts, PDPT should not be regarded as a first line approach to partner management. Really it is reserved for use with those partners who the patient believes will not get treatment unless they are brought the medication. And the medication used for PDPT should always come with thorough written education materials that explain about the infection, about the medication, and about where to find medical care.
California also supports the use of PDPT. Since 2001 for chlamydia, and since 2007 for gonorrhea, laws are in place that expressly allow clinicians to provide treatment to partners.
You may be interested in consulting the CDC’s webpages about PDPT. You’ll find a map of the U.S. that is constantly updated, as more states pass laws or regulations supporting PDPT, similar to those in California.
And you’ll find this tool kit about legal and policy issues.
For thorough guidance specific to the use of PDPT in California, visit the website of the STD Control Branch of the California Department of Public Health. Here you will find the most up-to-date information about the background to PDPT recommendations, and about implementing PDPT in your clinic.
Finally, let’s spend a few minutes to talk about a great program sponsored by the California Family Health Council, which supplies azithromycin to Title X clinics free of charge for use as PDPT.
Paying for the partner’s medication is often a barrier to treatment. Neither Medi-Cal nor Family PACT pays for PDPT. So several years ago, CFHC started an axithromycin distribution program, providing azithromycin to clinics like yours, specifially for use as PDPT.
Here are the requirement for use of this medications.
This is an example of the type of log you would keep.
During you site evaluations, these logs will be reviewed to asure compliance with the requirements of this program.
The California Family Health Council has examples of PDPT information factsheets in several languages, which you can use with PDPT. Here’s that web address…..
Your contact for more information about the azithromycin distribution program and any questions you may have is Aileen Barandas at CFHC; here is her email address and phone number. If you haven’t already, be sure to listen to the other 2 short webcasts, about the background reasons for PDPT, and about implementing the use of PDPT in your clinic setting. Thanks for listening to these webcasts, and thanks for the work you do.